Valuation: Azitra, Inc.

Market Cap 8.34M 7.41M 6.93M 6.31M 11.88M 803M 12.05M 83.8M 32.44M 409M 31.31M 30.63M 1.31B P/E 2026 *
-0.69x
P/E 2027 * -1.45x
Enterprise Value 8.34M 7.41M 6.93M 6.31M 11.88M 803M 12.05M 83.8M 32.44M 409M 31.31M 30.63M 1.31B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.41%
Yield 2026 *
-
Yield 2027 * -
1 day-6.61%
1 week-22.36%
Current month-6.61%
1 month-26.57%
3 months-23.42%
6 months-45.09%
Current year-51.47%
1 week 0.12
Extreme 0.1231
0.18
1 month 0.12
Extreme 0.1231
0.19
Current year 0.1
Extreme 0.1
0.38
1 year 0.1
Extreme 0.1
1.09
3 years 0.1
Extreme 0.1
455.54
5 years 0.1
Extreme 0.1
1,034.97
10 years 0.1
Extreme 0.1
1,034.97
Manager TitleAgeSince
Chief Executive Officer 56 01/04/2021
Chief Operating Officer 36 01/06/2023
Director of Finance/CFO 56 01/10/2022
Director TitleAgeSince
Director/Board Member 36 02/01/2014
Director/Board Member 56 01/04/2021
Director/Board Member 66 01/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
20/04/26 Free

Founder

64,300 0.3971%
20/04/26 Free

Chief Executive Officer

220,879 1.3641%
20/04/26 Free

Chief Financial Officer

35,524 0.2194%
Change 5-day change 1-year change 3-year change Capi.($)
-6.61%-22.36%-81.62%-99.96% 8.34M
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.69%+36.36%+82.72% 60.14B
-2.54%-0.21%+6.34%+31.72% 48.15B
-3.02%-2.67%+37.26%+32.51% 44.25B
+0.31%+7.94%+340.88%+643.82% 43.99B
-1.96%-1.71%+5.30%+99.46% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-4.86%-8.24%-24.60%+330.06% 24.93B
Average -0.70%+0.08%+41.72%+128.85% 39.68B
Weighted average by Cap. +0.18%+1.83%+60.06%+145.77%

Financials

2026 *2027 *
Net sales - -
Net income -12.45M -11.06M -10.34M -9.43M -17.75M -1.2B -17.99M -125M -48.44M -611M -46.75M -45.74M -1.96B -16.88M -14.99M -14.02M -12.77M -24.05M -1.62B -24.38M -170M -65.64M -827M -63.36M -61.99M -2.66B
Net Debt - -
Logo Azitra, Inc.
Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live bio therapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, chronic, xerotic (abnormally dry), and scaly skin disease.
Employees
-
Date Price Change Volume
02/10/26 $0.1285 -6.61% 1,351,309
30/09/26 $0.1376 +5.36% 611,017
29/09/26 $0.1306 -22.95% 3,214,474
28/09/26 $0.1695 +1.01% 617,078
25/09/26 $0.1678 +0.48% 159,308
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1376USD
Average target price
0.6700USD
Spread / Average Target
+386.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AZTR Stock